Investigational drug · Phase 2
A195
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Coronary Artery Disease (CAD).
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 12, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "A195"
First trial start
2025
Aug 27, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "A195", any sponsor or status.
Conditions studied
As listed on its trial records.
- Coronary Artery Disease (CAD)
Approved drugs for the same conditions: Coronary artery disease and heart attack
Largest trials
Live from ClinicalTrials.gov: studies naming "A195" as an intervention, largest first.
- Epicardial Delivery of XC001 Gene Therapy to Promote Angiogenesis in CAD Patients Undergoing Treatment With CABGPivotal-lookingNot yet recruiting
XyloCor Therapeutics, Inc.Industry
NCT07118449 · 116 participants (planned) · Start Aug 27, 2025 · Primary completion Dec 30, 2026
Drug: XC001; A195/placebo · For: Coronary Artery Disease (CAD)
Sites: Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- Isolation of a Variant of the Felid Herpesvirus 1-Live Attenuated Vaccine Strain F2 from Unvaccinated Cats.
Suga Y, Saito A, Kitamura Y, et al. · Intervirology 2026
- A spontaneous nonhuman primate model of inherited retinal degeneration.
Yi W, Xu M, Xue Y, et al. · JCI Insight 2025
- A Lipase Gene of Thermomyces lanuginosus: Sequence Analysis and High-Efficiency Expression in Pichia pastoris.
Yi L, Cheng L, Yang Q, et al. · Int J Mol Sci 2024
- Evidence-based practice - implementation level and attitude among physical, occupational, and speech and language therapists in Germany: status quo.
Reinecke S, Mijic M, Gerhard J, et al. · JBI Evid Implement 2024
- A Comparative Analysis of Polysaccharides and Ethanolic Extracts from Two Egyptian Sweet Potato Cultivars, Abees and A 195: Chemical Characterization and Immunostimulant Activities.
Elgabry RM, Hassan M, Fawzy GA, et al. · Metabolites 2024
- Recombinant adenovirus causes prolonged mobilization of macrophages in the anterior chambers of mice.
Meyer KJ, Pellack D, Hedberg-Buenz A, et al. · Mol Vis 2021
Also in development for Coronary Artery Disease (CAD)
- EA-230hourPhase 31 trial
EBI Anti Sepsis BV · Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
- SRSD107Phase 22 trials
Sirius Therapeutics Co., Ltd. · Venous Thromboembolism, Coronary Artery Disease (CAD), Peripheral Arterial Disease
- XC001Phase 21 trial
XyloCor Therapeutics, Inc. · Coronary Artery Disease (CAD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.